Genmab — September 2019
-
-
-
-
God morgen
-
-
Summary points from expert feedback:
Efficacy and safety of ofatumumab and Roche’s Ocrevus (ocrelizumab) look comparable suggesting convenience and price will be key differentiators
Ofatumumab’s subcutaneous delivery may be slightly preferable for new starts
Ocrevus’ longer B cell repletion cycle won’t necessarily be an issue unless an unexpected safety signal pops up
Ofatumumab could slightly curtail use of Ocrevus while also expanding anti-CD20 class -
God morgen
-
Vi kunne godt bruge en lille fredagsnyhed
-
Det kan vi hver fredag.
-
Tror de pt. er løbet tør...:-D
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind